Supplementary table II - Efficacy and tolerance of dupilumab in obese patients with moderate-to-severe atopic dermatitis. Dupuis et al
Published: 18 December 2023| Version 1 | DOI: 10.17632/8mbpb6snwz.1
Contributor:
Joséphine DupuisDescription
Supplementary table II: Dupilumab dose optimization and discontinuation.
Files
Institutions
Universite de Lille
Categories
Descriptive Table